Enterprise Value
-163.4M
Cash
236.6M
Avg Qtr Burn
-18.68M
Short % of Float
7.85%
Insider Ownership
18.63%
Institutional Own.
86.69%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zetomipzomib (KZR-616) Details Chronic inflammatory disorder, Chronic kidney disease, Inflammatory disease, Kidney disease, Lupus nephritis | Phase 2b Data readout | |
Zetomipzomib (KZR-616) Details Autoimmune Hepatitis | Phase 2a Data readout | |
KZR-261 Details Solid tumor/s | Phase 1 Data readout | |
KZR-616 Details Chronic inflammatory disorder, Inflammatory disease, Autoimmune disease | Failed Discontinued |